Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: dwight martin who wrote (21972)	6/8/1998 12:47:00 AM
From: Henry Niman	Respond to of 32384

Maybe the San Diego news will refocus the board. I'll post more details later, but it sounds like the SBH alliance will be expanded. Robinson said that SBH was "gobbling up the targets" related to the G-CSF mimic discovery. Robinson also indicated that their androgen program was the biggest (including pharmas) in world. LGND has 75 scientists working on various androgen projects, LGND has a proprietary position, and first compound, LGD1331, is an anti-androgen that should enter the clinic next year. ONTAK will cost about $40,000 per treatment and they are looking at non-Hodgkin lymphoma applications for the drug. They are looking to expand Panretin gel into basil and sq. cell carcinoma area. Targretin gel will be expanded to psoriasis indications (in addition to oral Targretin for that indication and breast cancer). Sounds like quite a bit is happening. I'll post details soon.

To: dwight martin who wrote (21972)	6/8/1998 12:59:00 AM
From: Henry Niman	Respond to of 32384

The FDA has come out with guidelines for Off-Label promotions: paradise-web.com

To: dwight martin who wrote (21972)	6/8/1998 8:01:00 AM
From: tonyt	Respond to of 32384

Good point. The 'poodle' is back to bark at the moon.

To: dwight martin who wrote (21972)	6/8/1998 8:48:00 AM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

In San Diego, Robinson also indicated that LGND was making excellent progress in their TZD program. Recently, WLA announced that the NIH diabetes prevention trial had discontinued using Rezulin because of one patient death. Bear Stearns (on Friday) came out with a WLA spot report on the news. They thought that it was odd that the NIH would discontinue Rezulin based on one patient death out of the 600 who had already enrolled. They think that WLA may initiate their own prevention study. They do not expect the FDA to make any changes and consider the NIH reaction as a medical non-event. They expect Rezulin sales to be about $600 million this year and $800 million next year.